N-甲氧基-1-(4-甲氧基苯基)甲胺 | 543731-16-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: N-甲氧基-1-(4-甲氧基苯基)甲胺
• 英文名称: N-(4-methoxybenzyl)-O-methylhydroxylamine
• 英文别名: N-methoxy-1-(4-methoxyphenyl)methanamine
• CAS: 543731-16-4
• 化学式: C₉H₁₃NO₂
• mdl: MFCD18825398
• 分子量: 167.208
• InChiKey: SHZLRNHMPUWSGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922299090

反应信息

• 作为反应物：
  描述：

  N-甲氧基-1-(4-甲氧基苯基)甲胺 在 咪唑 、 正丁基锂 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4,4-Diphenyl-4-trimethylsilanyloxy-but-2-ynyl)-N-(4-methoxy-benzyl)-O-methyl-hydroxylamine
  参考文献：
  名称：

  与烯丙基阳离子的分子内催化Friedel-Crafts反应，用于合成喹啉及其类似物。

  摘要：

  [反应：见正文]本文介绍了一种通过将烯基阳离子掺入催化的分子内Friedel-Crafts反应中来合成喹啉骨架的新方法。分别用酸和碱处理后，将起始产物异构化并加香，得到喹啉。基本概念也被证明对1-苯并ze庚因，1-苯并佐辛或异喹啉合成很有前景。

  DOI：

  10.1021/ol049301u
• 作为产物：
  描述：

  3-氯苯甲酰乙腈 、 4-甲氧基苯甲醛 在 盐酸 、 2-picoline borane 作用下， 以 甲醇 、 溶剂黄146 、 水 为溶剂， 反应 2.5h， 以92%的产率得到N-甲氧基-1-(4-甲氧基苯基)甲胺
  参考文献：
  名称：

  One-Pot Synthesis of Alkoxyamine Derivatives by Reductive Alkoxyamination with a 2-Picoline-Borane Complex

  摘要：

  Reduction of oxime ethers with a 2-picoline-borane complex was examined to give alkoxyamine derivatives. The reduction was found to proceed in the presence of aqueous HCl in MeOH-AcOH. The method was extended to one-pot synthesis of alkoxyamine derivatives from aldehydes and ketones. The reaction of carbonyl compounds with alkoxyamines in MeOH-AcOH (10:1), followed by sequential treatment with 2-picoline-borane and 3M HCl afforded alkoxyamine derivatives in good yields. This procedure can be applied to the synthesis of various alkoxyamine derivatives from aliphatic/aromatic aldehydes and ketones.

  DOI：

  10.3987/com-08-11532

文献信息

• HIV Integrase inhibitors
  申请人：——

  公开号：US20030176495A1

  公开（公告）日：2003-09-18

  The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the following formula, or a tautomer of said compound, or a pharmaceutically acceptable salt, solvate or prodrug thereof: 1 wherein R 1 , R 2 and B 1 are as defined herein.

  本发明涉及抑制HIV整合酶，以及通过给予以下化合物、该化合物的互变异构体、或其药学上可接受的盐、溶剂化合物或前药来治疗艾滋病或ARC的方法：1其中R1、R2和B1如本文所定义。
• HIV integrase inhibitors
  申请人：——

  公开号：US20040110804A1

  公开（公告）日：2004-06-10

  The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds. 1

  本发明描述了一种新的化合物I的组合，该组合可以抑制HIV整合酶。本发明还描述了使用这些化合物进行艾滋病或ARC治疗的组合和方法。
• HIV INTEGRASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1467695A2

  公开（公告）日：2004-10-20
• TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF
  申请人：Nanjing Transthera Biosciences Co., Ltd.

  公开号：US20210177828A1

  公开（公告）日：2021-06-17

  The present invention provides a novel inhibitor compound of general formula (I), exhibiting excellent kinase inhibitor activity. The compound of the present invention can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or ligands thereof. In addition, the compound of the present invention can also target CSF1R kinase, and thus can be used to prevent and/or treat diseases mediated by abnormal expression of TAM family kinase receptors and/or CSF1R kinase receptors and/or ligands thereof.
• HYDROGENATION PROCESS OF OXIME DERIVATIVES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：US20210387173A1

  公开（公告）日：2021-12-16

  The present invention relates to a novel process for the iridium-catalysed hydrogenation of oximes. The invention also relates to novel iridium catalysts for use in the iridium-catalysed hydrogenation of oximes and to processes of preparation of these catalysts. The invention further relates to the use of the novel iridium catalysts in ionic hydrogenation of other unsaturated substrates.